GET DAILY SIGNALSWhy Is BeyondSpring (BYSI) Stock Down -31.25% Today?
Key Takeaways
- BYSI shares fell about 31% in Tuesday's session, giving back a large portion of Monday's 44% surge.
- The primary catalyst was the announcement of an at-the-market (ATM) equity offering of up to 9.2 million shares, raising dilution concerns for a pre-revenue biotech.
- Profit-taking also weighed on the stock after Monday's sharp rally tied to an FDA Fast Track designation and a China strategic transaction.
- The strategic deal itself involves no cash consideration, which tempered investor enthusiasm.
- Traders are now watching execution of the ATM program, the DUBLIN-4 Phase 3 interim analysis, and near-term cash runway.
Opening Summary
BeyondSpring Inc. (BYSI), a clinical-stage biopharmaceutical company developing the late-stage immuno-oncology candidate Plinabulin, saw its shares reverse sharply on Tuesday, falling roughly 31.25% to about $0.77 after closing Monday's session at $1.12. The pullback follows a dramatic 44% rally in the prior session, as investors weighed a newly disclosed equity financing program against the positive regulatory news that drove the initial surge.
ATM Equity Offering Triggers Dilution Concerns
The dominant driver of Tuesday's decline was the company's disclosure that it had entered into an Open Market Sale Agreement with Citizens JMP Securities, establishing an at-the-market offering program under which it may sell up to 9.2 million ordinary shares from time to time. Based on the company's most recent reported sale price of $0.7772 per share, the full program could generate roughly $7.15 million in gross proceeds, with the sales agent entitled to a commission of up to 3%.
For a pre-revenue, cash-constrained biotech, the prospect of ongoing share issuance creates a meaningful dilution overhang. Investors frequently react negatively to ATM programs because the additional supply can pressure the share price, particularly in a thinly traded small-cap name. Net proceeds are earmarked for research and development and general corporate purposes, underscoring the company's continuing need to fund its clinical programs through external capital.
Profit-Taking After Monday's Sharp Rally
Tuesday's selloff also reflects classic give-back dynamics following an outsized single-day move. On Monday, BYSI shares surged more than 44% after the company announced that the U.S. Food and Drug Administration had granted Fast Track designation to Plinabulin in combination with docetaxel for advanced or metastatic non-squamous non-small cell lung cancer (NSCLC). The designation provides for more frequent FDA interactions and potential rolling review, but it does not assure faster approval.
The same announcement detailed a strategic transaction under which an investor will fund the China portion of the global Phase 3 DUBLIN-4 trial in exchange for the sale of a Chinese subsidiary. Because the deal involves no cash consideration, the near-term balance-sheet benefit is indirect, and some of Monday's momentum-driven buying unwound once the financing terms became clearer.
Market Context and Trading Activity
Trading activity has been exceptionally heavy relative to the stock's norm. Monday's session saw more than 2.4 million shares change hands, a dramatic increase versus the roughly 10,000-to-35,000-share daily volumes recorded in the preceding sessions. The elevated turnover reflects a mix of momentum traders, short-term speculators, and longer-term investors repositioning around the news flow.
The reversal in BYSI diverged from any single broad-market trend and appears to be company-specific, driven primarily by the newly announced share-sale program. Small-cap clinical-stage biotech names remain sensitive to financing announcements regardless of the direction of the broader equity indices, and dilution news tends to outweigh otherwise positive pipeline developments in the short term.
What Comes Next for BYSI
Looking ahead, investors will focus on several factors. The execution and pace of the ATM program will be closely watched, as continued share issuance could cap upside in the near term. On the clinical front, the market is tracking the DUBLIN-4 global Phase 3 trial, which plans to randomize approximately 442 patients and includes a prespecified interim analysis at 221 progression-free survival events; positive results could represent a significant value inflection point.
The strategic China arrangement is expected to substantially reduce the company's cash requirements for DUBLIN-4, with China enrollment anticipated to account for roughly half of the planned patient population. However, the transaction remains subject to closing conditions, and the company's overall cash position and path to funding remain key risks. As a pre-revenue developer, BYSI carries elevated volatility and binary-outcome risk tied to clinical and regulatory milestones.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots that are currently performing strongly under live market conditions. Tickeron offers hundreds of AI trading bots covering thousands of tickers, each varying by strategy, timeframe, performance metrics, and traded symbols, but only the strongest performers are featured in this dedicated section. Exploring the page can help traders discover automated strategies aligned with their own goals and risk tolerance.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
BYSI saw its Stochastic Oscillator leaves the overbought zone
The Stochastic Oscillator for BYSI moved out of overbought territory on November 04, 2026. This could be a bearish sign for the stock and investors may want to consider selling or taking a defensive position. A.I.dvisor looked at 44 similar instances where the indicator exited the overbought zone. In 40 of the 44 cases the stock moved lower. This puts the odds of a downward move at 90%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for BYSI moved out of overbought territory on November 03, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 23 similar instances where the indicator moved out of overbought territory. In 17 of the 23 cases, the stock moved lower in the following days. This puts the odds of a move lower at 74%.
BYSI moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BYSI crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 14 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BYSI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
BYSI broke above its upper Bollinger Band on November 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for BYSI entered a downward trend on November 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 30, 2026. You may want to consider a long position or call options on BYSI as a result. In 71 of 89 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 80%.
The Moving Average Convergence Divergence (MACD) for BYSI just turned positive on October 30, 2026. Looking at past instances where BYSI's MACD turned positive, the stock continued to rise in 39 of 50 cases over the following month. The odds of a continued upward trend are 78%.
Following a +55.97% 3-day Advance, the price is estimated to grow further. Considering data from situations where BYSI advanced for three days, in 174 of 217 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.724) is normal, around the industry mean (3.498). P/E Ratio (-3.682) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (31.056) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 80 (best 1 - 100 worst), indicating slightly worse than average price growth. BYSI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BYSI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of cancer therapies
Industry Biotechnology
Advertisement